Advertisement

Development of Agonists and Antagonists for Melatonin Receptors

  • Darius P. ZlotosEmail author
Chapter

Abstract

Numerous physiological actions of melatonin are mediated by two G-protein-coupled MT1 and MT2 receptors. The melatonergic drugs on the market, ramelteon and agomelatine, as well as the most advanced melatonergic ligands under clinical evaluation, tasimelteon and TIK-301, are high-affinity nonselective MT1 and MT2 agonists. However, exploring the exact physiological role of the MT1 and MT2 melatonin receptors requires subtype-selective MT1 and MT2 ligands. This chapter summarizes the progress in the development of melatonergic agonists and antagonists focusing on high-affinity and subtype-selective agents.

Keywords

Melatonin Melatonin receptor agonists Melatonin receptor antagonists Melatonin receptor partial agonists MT1 receptors MT2 receptors Selective ligands 

References

  1. 1.
    Reppert SM, Weaver DR, Godson C. Melatonin receptors step into the light: cloning and classification of subtypes. Trends Pharmacol Sci. 1996;17:100–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JL, Delagrange P, Canet E, Boutin JA. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J Biol Chem. 2000;275:31311–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Li P-K, Witt-Enderby PA. Melatonin receptors as potential targets for drug discovery. Drug Future. 2000;25:945–57.Google Scholar
  4. 4.
    Dubocovich ML, Yun K, Al-Ghoul WM, Benloucif S, Masana MI. Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms. FASEB J. 1998;12:1211–20.PubMedGoogle Scholar
  5. 5.
    Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff VK, Reppert SM. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron. 1997;19:91–102.PubMedCrossRefGoogle Scholar
  6. 6.
    Doolen S, Krause DN, Dubocovich ML, Duckles SP. Melatonin mediates two distinct responses in vascular smooth muscle. Eur J Pharmacol. 1998;345:67–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Hunt AE, Al-Ghoul WM, Gillette MU, Dubocovich ML. Activation of MT(2) melatonin receptors in rat suprachiasmatic nucleus phase advances the circadian clock. Am J Physiol. 2001;280:C110–8.Google Scholar
  8. 8.
    Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005;27:101–10.PubMedCrossRefGoogle Scholar
  9. 9.
    Hardeland R. New approaches in the management of insomnia: weighing the advantages of prolonged release melatonin and synthetic melatoninergic agonists. Neuropsychiatr Dis Treat. 2009;5:341–54.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Gershell L. Insomnia market. Nature Rev Drug Discov. 2006;5:15–7.CrossRefGoogle Scholar
  11. 11.
    Pandi-Perumal SR, Srinivasan V, Poeggeler B, Hardeland R, Cardinali DP. Drug insight: the use of melatonergic agonists for the treatment of insomnia – focus on ramelteon. Nat Clin Pract Neurol. 2007;3:221–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Miyamoto M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders. CNS Neurosci Ther. 2009;15:32–51.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ. Agomelatine, the first melatonergic antidepressant: discovery characterization and development. Nat Rev Drug Discov. 2010;9:628–42.PubMedCrossRefGoogle Scholar
  14. 14.
    Lankford DA. Tasimelteon for insomnia. Expert Opin Investig Drugs. 2011;20:987–93.PubMedCrossRefGoogle Scholar
  15. 15.
    Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist β-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry. 2005;66:384–90.PubMedCrossRefGoogle Scholar
  16. 16.
    Landolt HP, Wehrle R. Antagonism of serotonergic 5-HT2A/2C receptors: mutual improvement of sleep, cognition and mood? Eur J Neurosci. 2009;29:1795–809.PubMedCrossRefGoogle Scholar
  17. 17.
    Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem. 2008;8:954–68.PubMedCrossRefGoogle Scholar
  18. 18.
    Mor M, Rivara S, Pala D, Bedini A, Spadoni G, Tarzia G. Recent advances in the development of melatonin MT1 and MT2 receptor agonists. Expert Opin Ther Pat. 2010;20:1059–77.PubMedCrossRefGoogle Scholar
  19. 19.
    Hardeland R. Investigational melatonin receptor agonists. Expert Opin Investig Drugs. 2010;19:747–64.PubMedCrossRefGoogle Scholar
  20. 20.
    Sumaya IC, Masana MI, Dubocovich ML. The antidepressant-like effect of the melatonin receptor ligand luzindole in mice during forced swimming requires expression of MT2 but not MT1 melatonin receptors. J Pineal Res. 2005;39:170–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Li XM, Beau J, Delagrange P, Mocaer E, Lévi F. Circadian rhythm entrainment with melatonin, melatonin receptor antagonist S22153 or their combination in mice exposed to constant light. J Pineal Res. 2004;37:176–84.PubMedCrossRefGoogle Scholar
  22. 22.
    Willis GL. The role of ML-23 and other melatonin analogues in the treatment and management of Parkinson’s disease. Drug News Perspect. 2005;18:437–44.PubMedCrossRefGoogle Scholar
  23. 23.
    Ochoa-Sanchez R, Comai S, Lacoste B, Bambico FR, Dominguez-Lopez S, Spadoni G, Rivara S, Bedini A, Angeloni D, Fraschini F, Mor M, Tarzia G, Descarries L, Gobbi G. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci. 2011;31:18452–39.CrossRefGoogle Scholar
  24. 24.
    Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm ChemLife Sci. 2005;338:229–47.CrossRefGoogle Scholar
  25. 25.
    Zlotos DP. Recent progress in the development of agonists and antagonists for melatonin receptors. Curr Med Chem. 2012;19:3532–49.PubMedCrossRefGoogle Scholar
  26. 26.
    Dubocovich ML, Cardinali DP, Delagrange P, Krause DN, Strosberg AD, Sugden D, Yocca FD. Melatonin receptors. In: Girdlestone D, editor. The IUPHAR compendium of receptor characterization and classification. 2nd ed. London: IUPHAR Media; 2000. p. 270–7.Google Scholar
  27. 27.
    Dubocovich ML, Masana MI, Iacob S, Sauri DM. Melatonin receptor antagonists that differentiate between the human Mel1aand Mel1b recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML1 presynaptic heteroreceptor. Naunyn Schmiedebergs Arch Pharmacol. 1997;355:365–75.PubMedCrossRefGoogle Scholar
  28. 28.
    Faust R, Garratt PJ, Trujillo Pèrez MA, Piccio VJD, Madsen C, Stenstrom A, Frolund B, Davidson K, Teh MT, Sugden D. 7-substituted-melatonin and 7-substituted-1-methylmelatonin analogues: effect of substituents on potency and binding affinity. Bioorg Med Chem. 2007;15:4543–51.PubMedCrossRefGoogle Scholar
  29. 29.
    Leclerc V, Saıd Y, Delagrange P, Boutin JA, Renard P, Lesieur D. Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT3. J Med Chem. 2002;45:1853–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Nonno R, Lucini V, Spadoni G, Pannacci M, Croce A, Esposti D, Balsamini C, Tarzia G, Fraschini F, Stankov BM. A new melatonin receptor ligand with mt1-agonist and MT2-antagonist properties. J Pineal Res. 2000;29:234–40.PubMedCrossRefGoogle Scholar
  31. 31.
    Spadoni G, Bedini A, Guidi T, Tarzia G, Lucini V, Pannacci M, Fraschini F. Towards the development of mixed MT1-agonist/MT2-antagonist melatonin receptor ligands. Chem Med Chem. 2006;1:1099–105.PubMedCrossRefGoogle Scholar
  32. 32.
    Elsner J, Boeckler F, Davidson K, Sugden D, Gmeiner P. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: synthesis, biological evaluation, and molecular modelling of the putative bioactive conformation. Bioorg Med Chem. 2006;14:1949–58.PubMedCrossRefGoogle Scholar
  33. 33.
    El Kazzouli S, du Bellay AG, Berteina-Raboin S, Delagrange P, Caignard DH, Guillaumet G. Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands. Eur J Med Chem. 2011;46:4252–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Tarzia G, Diamantini G, Di Giacomo B, Spadoni G, Esposti D, Nonno R, Lucini V, Pannacci M, Fraschini F, Stankov BM. 1-(2-alkanamidoethyl)-6-methoxyindole derivatives: a new class of potent indole melatonin analogues. J Med Chem. 1997;40:2003–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Jeanty M, Suzenet F, Delagrange F, Nosjean O, Boutin JA, Caignard DH, Guillaumet G. Design and synthesis of 1-(2-alkanamidoethyl)-6-methoxy-7-azaindolederivatives as potent melatonin agonists. Bioorg Med Chem Lett. 2011;21:2316–9.PubMedCrossRefGoogle Scholar
  36. 36.
    Wallez V, Durieux-Poissonnier S, Chavatte P, Boutin JA, Audinot V, Nicolas J-P, Bennejean C, Delagrange P, Renard P, Lesieur D. Synthesis and structure − affinity − activity relationships of novel benzofuran derivatives as MT2 melatonin receptor selective ligands. J Med Chem. 2002;45:2788–800.PubMedCrossRefGoogle Scholar
  37. 37.
    Audinot V, Mailliet F, Lahaye-Brasseur C, Bonnaud A, Le Gall A, Amossé C, Dromaint S, Rodriguez M, Nagel N, Galizzi JP, Malpaux B, Guillaumet G, Lesieur D, Lefoulon F, Renard P, Delagrange P, Boutin JA. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2003;367:553–61.PubMedCrossRefGoogle Scholar
  38. 38.
    Koike T, Hoashi Y, Takai T, Nakayama M, Yukuhiro N, Ishikawa T, Hirai K, Uchikawa O. 1,6-dihydro-2H-indeno[5,4-b]furan derivatives: design, synthesis, and pharmacological characterization of a novel class of highly potent MT2-selective agonists. J Med Chem. 2011;54:3436–44.PubMedCrossRefGoogle Scholar
  39. 39.
    Koike T, Takai T, Hoashi Y, Nakayama M, Kosugi Y, Nakashima M, Yoshikubo S, Hirai K, Uchikawa O. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands. J Med Chem. 2011;54:4207–18.PubMedCrossRefGoogle Scholar
  40. 40.
    Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881–90.PubMedCrossRefGoogle Scholar
  41. 41.
    Garratt PJ, Travard S, Vonhoff S, Tsotinis A, Sugden D. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J Med Chem. 1996;39:1797–805.PubMedCrossRefGoogle Scholar
  42. 42.
    Carocci A, Catalano A, Lovece A, Lentini G, Duranti A, Lucini V, Pannacci M, Scaglione F, Franchini C. Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors. Bioorg Med Chem. 2010;18:6496–551.PubMedCrossRefGoogle Scholar
  43. 43.
    Tsotinis A, Vlachou M, Papahatjis DP, Calogeropoulou T, Nikas SP, Garratt PJ, Piccio V, Vonhoff S, Davidson K, Teh MT, Sugden D. Mapping the melatonin receptor. 7. Subtype selective ligands based on β-substituted N-acyl-5-methoxytryptamines and N-acyl-5-methoxy-1-methyl-tryptamines. J Med Chem. 2006;49:3509–19.PubMedCrossRefGoogle Scholar
  44. 44.
    Markl C, Attia MI, Julius J, Witt-Enderby PA, Zlotos DP. 1,2,3,4-tetrahydropyrazino[1,2-a]indole and 2-[(phenylmethylamino)methyl]-1H-indole analogues: probing the pharmacophore for MT2-selective melatonin receptor ligands. Bioorg Med Chem. 2009;17:826–33.CrossRefGoogle Scholar
  45. 45.
    Attia MI, Julius J, Witt-Enderby PA, Zlotos DP. Synthesis and pharmacological evaluation of 13a,14-dihydro-6H, 13H-pyrazino[1,2-a;4,5-a’]diindole analogs as melatonin receptor ligands. Tetrahedron. 2007;63:754–60.CrossRefGoogle Scholar
  46. 46.
    Attia MI, Witt-Enderby PA, Julius J. Synthesis and pharmacological evaluation of pentacyclic 6a,7-dihydrodiindole and 2,3-dihydrodiindole derivatives as novel melatoninergic ligands. Bioorg Med Chem. 2008;16:7654–61.PubMedCrossRefGoogle Scholar
  47. 47.
    Rivara S, Diamantini G, Di Giacomo B, Lamba D, Gatti G, Lucini V, Pannacci M, Mor M, Spadoni G, Tarzia G. Reassessing the melatonin pharmacophore-enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorg Med Chem. 2006;14:3383–91.PubMedCrossRefGoogle Scholar
  48. 48.
    Di Giacomo B, Bedini A, Spadoni G, Tarzia G, Fraschini F, Pannacci M, Lucini V. Synthesis and biological activity of new melatonin dimeric derivatives. Bioorg Med Chem. 2007;15:4643–50.PubMedCrossRefGoogle Scholar
  49. 49.
    Li G, Zhou H, Jiang Y, Keim H, Topiol SW, Poda SB, Ren Y, Chandrasena G, Doller D. Design and synthesis of 4-arylpiperidinyl amide and N-arylpiperdin-3-yl-cyclopropane carboxamide derivatives as novel melatonin receptor ligands. Bioorg Med Chem Lett. 2011;21:1236–42.PubMedCrossRefGoogle Scholar
  50. 50.
    Sun L-Q, Chen J, Mattson R, Epperson JR, Deskus JA, Li W, Takaki K, Hodges DB, Iben L, Mahle CD, Ortiz A, Molstad D, Ryan E, Yeleswaram K, Xu C, Luo G. Heterocyclic aminopyrrolidine derivatives as melatoninergic agents Bioorg. Med Chem Lett. 2003;13:4381–4.CrossRefGoogle Scholar
  51. 51.
    Rivara S, Lodola A, Mor M, Bedini A, Spadoni G, Lucini V, Pannacci M, Fraschini F, Scaglione F, Sanchez RO, Gobbi G, Tarzia G. N-(Substituted-anilinoethyl)amides: design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem. 2007;50:6618–26.PubMedCrossRefGoogle Scholar
  52. 52.
    Spadoni G, Bedini A, Diamantini G, Tarzia G, Rivara S, Lorenzi S, Lodola A, Mor M, Lucini V, Pannacci M, Caronno A, Fraschini F. Synthesis, enantiomeric resolution, and structure-activity relationship of a series of 10,11-dihydro-5H-dibenzo[a,d]cycloheptene MT2 receptor antagonists. Chem Med Chem. 2007;2:1741–9.PubMedCrossRefGoogle Scholar
  53. 53.
    Rivara S, Lorenzi S, Mor M, Plazzi PV, Spadoni G, Bedini A, Tarzia G. Analysis of structure-activity relationships for MT2 selective antagonists by melatonin MT1 and MT2 receptor models. J Med Chem. 2005;48:4049–60.PubMedCrossRefGoogle Scholar
  54. 54.
    Lucarini S, Bartolucci S, Bedini A, Gatti G, Orlando P, Piersanti G, Spadoni G. Synthesis and configuration determination of all enantiopure stereoisomers of the melatonin receptor ligand 4-phenyl-2-propionamidotetralin using an expedient optical resolution of 4-phenyl-2-tetralone. Org Biomol Chem. 2012;10:305–13.PubMedCrossRefGoogle Scholar
  55. 55.
    Bedini A, Lucarini S, Spadoni G, Tarzia G, Scaglione F, Dugnani S, Pannacci M, Lucini V, Carmi C, Pala D, Rivara S, Mor M. Toward the definition of stereochemical requirements forMT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives. J Med Chem. 2011;54:8362–72.PubMedCrossRefGoogle Scholar
  56. 56.
    Durieux S, Chanu A, Bochu C, Audinot V, Coumailleau S, Boutin JA, Delagrange P, Caignard DH, Bennejean C, Renard P, Lesieur D, Berthelot P, Yous S. Design and synthesis of 3-phenyltetrahydronaphthalenic derivatives as new selective MT2 melatoninergic ligands. Part II. Bioorg Med Chem. 2009;17:2963–74.PubMedCrossRefGoogle Scholar
  57. 57.
    Poissonnier-Durieux S, Ettaoussi M, Pérès B, Boutin JA, Audinot V, Bennejean C, Delagrange P, Caignard DH, Renard P, Berthelot P, Lesieur D, Yous S. Synthesis of 3-phenylnaphthalenic derivatives as new selective MT2 melatoninergic ligands. Bioorg Med Chem. 2008;16:8339–48.PubMedCrossRefGoogle Scholar
  58. 58.
    Bedini A, Spadoni G, Gatti G, Lucarini S, Tarzia G, Rivara S, Lorenzi S, Lodola A, Mor M, Lucini V, Pannacci M, Scaglione F. Design and synthesis of N-(3,3-diphenylpropenyl)alkanamides as a novel class of high-affinity MT2-selective melatonin receptor ligands. J Med Chem. 2006;49:7393–403.PubMedCrossRefGoogle Scholar
  59. 59.
    Hu Y, Ho MKC, Chan KH, New DC, Wong YH. Synthesis of substituted N-[3-(3-methoxyphenyl) propyl] amides as highly potent MT2-selective melatonin ligands. Bioorg Med Chem Lett. 2010;20:2582–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Heckman D, Attia MI, Behnam MAM, Mohsen AMY, Markl C, Julius J, Sethi S, Witt-Enderby PA, Zlotos DP. 2-[(1,3-Dihydro-2H-isoindol-2yl)methyl]-melatonin – a novel MT2-selective melatonin receptor antagonist. Med Chem Commun. 2011;2:991–4.CrossRefGoogle Scholar
  61. 61.
    Chan KH, Hu Y, Ho MKC, Wong YH. Characterization of substituted phenylpropylamides as highly selective agonists at the melatonin MT2 receptor. Curr Med Chem. 2013;20:289–300.PubMedCrossRefGoogle Scholar
  62. 62.
    Zlotos DP, Attia MI, Julius J, Sethi S, Witt-Enderby PA. 2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. J Med Chem. 2009;52:826–33.PubMedCrossRefGoogle Scholar
  63. 63.
    Mésangeau C, Fraise M, Delagrange P, Caignard DH, Boutin JA, Berthelot P, Yous S. Preparation and pharmacological evaluation of a novel series of 2-(phenylthio) benzo[b]thiophenes as selective MT2 receptor ligands. Eur J Med Chem. 2011;46:1835–40.PubMedCrossRefGoogle Scholar
  64. 64.
    Descamps-Francois C, Yous S, Chavatte P, Audinot V, Bonnaud A, Boutin JA, Delagrange P, Bennejean C, Renard P, Lesieur D. Design and synthesis of naphthalenic dimers as selective MT1 melatoninergic ligands. J Med Chem. 2003;46:1127–9.PubMedCrossRefGoogle Scholar
  65. 65.
    Mesangeau C, Peres B, Descamps-Francois C, Chavatte P, Audinot V, Coumailleau S, Boutin JA, Delagrange P, Bennejean C, Renard P, Caignard DH, Berthelot P, Yous S. Design, synthesis and pharmacological evaluation of novel naphthalenic derivatives as selective MT1 melatoninergic ligands. Bioorg Med Chem. 2010;18:3426–36.PubMedCrossRefGoogle Scholar
  66. 66.
    Sun LQ, Chen J, Bruce M, Deskus JA, Epperson JR, Takaki K, Johnson G, Iben L, Mahle CD, Ryan E, Xu C. Synthesis and structure–activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett. 2004;14:3799–802.PubMedCrossRefGoogle Scholar
  67. 67.
    Markl C, Clafshenkel WP, Attia MI, Sethi S, Witt-Enderby PA, Zlotos DP. N-acetyl-5-arylalkoxytryptamine analogs: probing the melatonin receptors for MT1-selectivity. Arch Pharm Chem Life Sci. 2011;334:666–74.CrossRefGoogle Scholar
  68. 68.
    Spadoni G, Bedini A, Orlando P, Lucarini S, Tarzia G, Mor M, Rivara S, Lucini V, Pannacci M, Scaglione F. Bivalent ligand approach on N-{2-[(3-methoxyphenyl)methylamino]ethyl}-acetamide: synthesis, binding affinity and intrinsic activity forMT1 and MT2 melatonin receptors. Bioorg Med Chem. 2011;19:4910–6.PubMedCrossRefGoogle Scholar
  69. 69.
    Rivara S, Pala D, Lodola A, Mor M, Lucini V, Dugnani S, Scaglione F, Bedini A, Lucarini S, Tarzia G, Spadoni G. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides. Chem Med Chem. 2012;7:1954–64.PubMedCrossRefGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  1. 1.Department of Pharmaceutical Chemistry, Faculty of Pharmacy and BiotechnologyThe German University in CairoNew Cairo CityEgypt

Personalised recommendations